SEMA4D encodes semaphorin 4D which is inhibited by pepinemab, an antibody that has been clinically studied for treatment of several cancer types, including a phase I trial of CRC (Clinicaltrials.gov: NCT03373188). Here, SEMA4D is linked to colorectal carcinoma.